We are experts in developing novel sub-unit vaccines Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner. Our current portfolio comprises 6 vaccines across livestock species. Proof of concepts have been generated in > 20 additional vaccine antigens Value through collaborations Our go to market strategy is inherently linked to collaborations. We offer: • Development of tailor-made baculovirus vectors optimized for industrial production. • Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®. • Supply of recombinant proteins produced in CrisBio® through license agreements. • Development of proprietary portfolios. Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.
